Evidence map›Paper›PMID 29152663›Full record

ArticleMolecular medicine reports2017

MicroRNA‑137 has a suppressive role in liver cancer via targeting EZH2.

Shichang Cui, Yanlei Sun, Yang Liu, Chengbiao Liu, Jinbao Wang, Guang Hao, Qidong Sun

RetractedErratum issuedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Shichang CuiDepartment of General Surgery, Central Hospital of Linyi, Linyi, Shandong 276400, P.R. China.
Yanlei SunDepartment of General Surgery, Central Hospital of Linyi, Linyi, Shandong 276400, P.R. China.
Yang LiuDepartment of Obstetrics and Gynecology, Central Hospital of Linyi, Linyi, Shandong 276400, P.R. China.
Chengbiao LiuDepartment of General Surgery, Central Hospital of Linyi, Linyi, Shandong 276400, P.R. China.
Jinbao WangDepartment of General Surgery, Central Hospital of Linyi, Linyi, Shandong 276400, P.R. China.
Guang HaoDepartment of General Surgery, Central Hospital of Linyi, Linyi, Shandong 276400, P.R. China.
Qidong SunDepartment of General Surgery, Central Hospital of Linyi, Linyi, Shandong 276400, P.R. China.
Linyi People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A variety of microRNAs (miRs) have been demonstrated to be associated with the development and malignant progression of human cancer; however, the regulatory mechanism of miR‑137 underlying hepatocellular carcinoma (HCC) growth and metastasis still remains to be fully revealed. In the present study, reverse transcription‑quantitative polymerase chain reaction and western blot were used to examine mRNA and protein expression. MTT assay, wound healing assay and Transwell assay were performed to determine cell proliferation, migration and invasion. Luciferase reporter assay was conducted to confirm the targeting relationship. miR‑137 was significantly downregulated in HCC tissues compared to adjacent normal tissues. Low expression of miR‑137 was significantly associated with lymph node metastasis, vein invasion, advanced clinical stage and poor prognosis in HCC. In addition, miR‑137 was also downregulated in several liver cancer cell lines compared with normal liver epithelial cells. Overexpression of miR‑137 led to a significant reduction in cell proliferation, migration and invasion of HepG2 cells. Enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) was further identified as a direct target gene of miR‑137, and the protein expression of EZH2 was negatively regulated by miR‑137 in HepG2 cells. Additionally, EZH2 was significantly upregulated in HCC tissues and liver cancer cell lines. Furthermore, overexpression of EZH2 significantly eliminated the inhibitory effects of miR‑137 on the malignant phenotypes of HepG2 cells. Therefore, the findings suggest that miR‑137 may have a suppressive role in HCC growth and metastasis via targeting EZH2.

Indexed as

AdultAgedCarcinoma, HepatocellularCell MovementCell ProliferationEnhancer of Zeste Homolog 2 ProteinFemaleGene Expression Regulation, NeoplasticHep G2 CellsHumansLiver NeoplasmsMaleMicroRNAsMiddle AgedNeoplasm InvasivenessEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanMicroRNAsMIRN137 microRNA, human

Identifiers

PMID29152663
PMCPMC5780008
OpenAlexW2766736294

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.